

In the Claims

1. (Previously presented) A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration, said formulation comprising particles, the cores of which comprise an SSRI which is fluvoxamine or a pharmaceutically-acceptable salt thereof, said core having thereon a rate-controlling membrane coating which allows controlled release of said SSRI over a period of not less than about 12 hours following oral administration.
2. (Original) A formulation according to Claim 1, wherein the particles are pellets.
3. (Cancelled)
4. (Previously presented) A formulation according to Claim 2, wherein the rate-controlling membrane coating comprises a mixture of a major proportion of a pharmaceutically acceptable film-forming, water-insoluble polymer and a minor proportion of a pharmaceutically acceptable film-forming, water-soluble polymer in a selected ratio, the selected ratio of said water-insoluble polymer to said water-soluble polymer being effective to permit a SSRI release rate which allows controlled release of said SSRI over a period of not less than about 12 hours following oral administration.
5. (Previously presented) A formulation according to Claim 4, wherein the rate-controlling membrane coating contains an ammonio methacrylate co-polymer.

Claims 6 to 19 (Cancelled)

20. (Previously presented) A formulation according to Claim 1, wherein the core further comprises an organic acid, the SSRI component and the organic acid being present in a ratio of from 50:1 to 1:50.
21. (Cancelled)
22. (Cancelled)
23. (Previously presented) A formulation according to Claim 1, wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the core and is formed from a lacquer substance comprising ammonio methacrylate copolymer and wherein the SSRI release rate from the particles exhibits the following *in vitro* dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
 - (a) no more than about 15% of the total SSRI is released after 0.5 of an hour of measurement in said apparatus;
 - (b) no more than about 25% of the total SSRI is released after 1 hour of measurement in said apparatus;

- (c) between about 20% and about 75% of the total SSRI is released after 2 hours of measurement in said apparatus;
 - (d) not less than about 75% of the total SSRI is released after 4 hours of measurement in said apparatus; and
 - (e) not less than about 85% of the total SSRI is released after 6 hours of measurement in said apparatus.
24. (Previously presented) A formulation according to Claim 1, wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the core and is formed from a lacquer substance comprising ammonio methacrylate copolymer and wherein the SSRI release rate from the particles exhibits the following *in vitro* dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
- (a) no more than about 20% of the total SSRI is released after 4 hours of measurement in said apparatus;
 - (b) no more than about 45% of the total SSRI is released after 6 hours of measurement in said apparatus;
 - (c) between about 45% and 80% of the total SSRI is released after 8 hours of measurement in said apparatus;

- (d) not less than about 70% of the total SSRI is released after 10 hours of measurement in said apparatus; and
 - (e) not less than about 80% of the total SSRI is released after 12 hours of measurement in said apparatus.
25. (Previously presented) A formulation according to Claim 1 in a form suitable for oral administration.
26. (Previously presented) A formulation according to Claim 1 in a form suitable for oral administration and comprising a blend of said particles in admixture with an immediate release form of SSRI or a pharmaceutically acceptable salt thereof to ensure a rapid attainment of effective therapeutic blood levels.
27. (Previously presented) A formulation according to Claim 26, wherein the immediate release form of SSRI comprises pellets.
28. (Previously presented) A formulation according to Claim 25, wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the core and is formed from a lacquer substance comprising ammonio methacrylate copolymer and wherein the SSRI release rate from the particles exhibits the following *in vitro* dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopoeia XXII in 0.05 M phosphate buffer at pH 6.8:

- (a) no more than about 20% of the total SSRI is released after 1 hour of measurement in said apparatus;
 - (b) no more than about 60% of the total SSRI is released after 2 hours of measurement in said apparatus;
 - (c) not less than about 20% of the total SSRI is released after 4 hours of measurement in said apparatus;
 - (d) not less than about 35% of the total SSRI is released after 6 hours of measurement in said apparatus;
 - (e) not less than about 50% of the total SSRI is released after 8 hours of measurement in said apparatus;
 - (f) not less than about 70% of the total SSRI is released after 10 hours of measurement in said apparatus; and
 - (g) not less than about 75% of the total SSRI is released after 12 hours of measurement in said apparatus.
29. (Previously presented) A formulation according to Claim 25, wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the core and is formed from a lacquer substance comprising ammonio methacrylate copolymer and wherein the SSRI release rate from the particles exhibits the following *in vitro* dissolution pattern when measured

using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:

- (a) no more than about 20% of the total SSRI is released after 1 hour of measurement in said apparatus;
 - (b) no more than about 45% of the total SSRI is released after 2 hours of measurement in said apparatus;
 - (c) between about 20% and about 70% of the total SSRI is released after 4 hours of measurement in said apparatus;
 - (d) between about 35% and about 85% of the total SSRI is released after 6 hours of measurement in said apparatus;
 - (e) not less than about 50% of the total SSRI is released after 8 hours of measurement in said apparatus.
 - (f) not less than about 70% of the total SSRI is released after 10 hours of measurement in said apparatus; and
 - (g) not less than about 75% of the total SSRI is released after 12 hours of measurement in said apparatus.
30. (Previously presented) A formulation according to Claim 1, wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the

core and is formed from a lacquer substance comprising ammonio methacrylate copolymer and wherein the SSRI release rate from the particles exhibits the following *in vitro* dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:

- (a) no more than about 50% of the total SSRI is released after 2 hours of measurement in said apparatus;
 - (b) not less than about 35% of the total SSRI is released after 6 hours of measurement in said apparatus; and
 - (c) not less than about 80% of the total SSRI is released after 22 hours of measurement in said apparatus.
31. (Previously presented) A formulation according to Claim 4, wherein the core further comprises an organic acid, the SSRI component and the organic acid being present in a ratio of from 50:1 to 1:50.
32. (Previously presented) A formulation according to Claim 5, wherein the core further comprises an organic acid, the SSRI component and the organic acid being present in a ratio of from 50:1 to 1:50.
33. (Previously presented) A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of said conditions a therapeutically effective amount of a multiparticulate controlled release

SSRI formulation according to Claim 1.

34. (Previously presented) A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of said conditions a therapeutically effective amount of a multiparticulate controlled release SSRI formulation according to Claim 25.
35. (Previously presented) A formulation according to Claim 2, wherein the rate-controlling membrane coating comprises a pharmaceutically acceptable film-forming, water-insoluble polymer in an amount effective to obtain a controlled release of a SSRI over a period of not less than about 12 hours following oral administration.
36. (Previously presented) The formulation according to Claim 1, wherein said rate controlling polymer is SSRI-permeable.
37. (Previously presented) The formulation according to Claim 1, wherein said rate controlling polymer is SSRI-permeable and water soluable.
38. (Previously presented) The formulation according to Claim 1, wherein said rate controlling polymer is SSRI-permeable and water insoluable.
39. (Previously presented) The formulation according to Claim 25, wherein said formulation is in capsule form.

40. (Previously presented) The formulation according to Claim 25, wherein said formulation is in tablet form.

Claims 41 to 44 (Cancelled)

45. (Previously presented) A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of said conditions a therapeutically effective amount of a multiparticulate controlled release SSRI formulation according to Claim 24.
46. (Previously presented) The formulation according to Claim 24, wherein said formulation is in tablet form.
47. (Previously presented) A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration, which comprises particles, the core of which comprises an SSRI which is fluvoxamine or a pharmaceutically-acceptable salt thereof, said core coated with a rate-controlling polymeric acrylate or methacrylate lacquer substance which allows controlled release of said SSRI over a period of not less than about 12 hours following oral administration.
48. (Previously presented) A formulation according to Claim 47 wherein said substance is said acrylate lacquer.
49. (Previously presented) A formulation according to Claim 47 wherein said substance is said methacrylate lacquer.

50. (Previously presented) A formulation according to Claim 47 wherein said substance is a lacquer which contains a mixture of said acrylate and methacrylate.
51. (Previously presented) A formulation according to Claim 47 wherein said substance is an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters having a low content of quaternary ammonium groups.

Claims 52 to 54 (Cancelled)

55. (Previously presented) The formulation of Claim 1 wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the core and is formed from a lacquer substance comprising ammonio methacrylate copolymer and wherein.
56. (Previously presented) The formulation of Claim 55 wherein said weight gain is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the core.
57. (Previously presented) A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of said conditions a therapeutically effective amount of a multiparticulate controlled release SSRI formulation according to Claim 55.

58. (New) The formulation of Claim 55 wherein said weight gain is in an amount of about 8% of the weight of the core.
59. (New) A unit dose formulation which is effective in supplying fluvoxamine to the blood of a patient such that, following a single application of the unit dose to the patient, the amount of circulating fluvoxamine ($AUC_{0-\infty}$) in the blood serum of the patient is about 275 to about 1,900 ng/ml.h, said formulation comprising particles, the cores of which comprise an SSRI which is fluvoxamine or a pharmaceutically-acceptable salt thereof, said core having thereon a rate-controlling membrane coating which allows controlled release of said SSRI over a period of not less than about 12 hours following oral administration.
60. (New) The formulation of Claim 58 wherein said membrane coating is present in an amount such that it contributes to the particle a weight gain of from about 4% to about 15% of the weight of the core and is formed from a lacquer substance comprising ammonio methacrylate copolymer.
61. (New) The formulation of Claim 59 wherein said weight gain is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the core.
62. (New) The formulation of Claim 58 wherein said amount of circulating fluvoxamine ($AUC_{0-\infty}$) in the blood serum of the patient is about 275 to about 1,175 ng/ml.h.

SYNNESTVEDT & LECHNER LLP
Group No. 1615
U.S. Application No. 09/744,169

August 31, 2005
S&L File No. P 24,622-A USA

63. (New) The formulation of Claim 60 wherein said weight gain is in an amount of about 8% of the weight of the core: